Overall Survival Benefit Update From RATIONALE-305

Opinion
Video

Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma.

Recent Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
1 KOL is featured in this series.